Endothelin-1 is increased in the plasma of patients hospitalised with Covid-19

Virus induced endothelial dysregulation is a well-recognised feature of severe Covid-19 infection. Endothelin-1 (ET-1) is the most highly expressed peptide in endothelial cells and a potent vasoconstrictor, thus representing a potential therapeutic target. ET-1 plasma levels were measured in a cohor...

Descripción completa

Detalles Bibliográficos
Autores principales: Abraham, George R., Kuc, Rhoda E., Althage, Magnus, Greasley, Peter J., Ambery, Philip, Maguire, Janet J., Wilkinson, Ian B., Hoole, Stephen P., Cheriyan, Joseph, Davenport, Anthony P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academic Press 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941861/
https://www.ncbi.nlm.nih.gov/pubmed/35339512
http://dx.doi.org/10.1016/j.yjmcc.2022.03.007
Descripción
Sumario:Virus induced endothelial dysregulation is a well-recognised feature of severe Covid-19 infection. Endothelin-1 (ET-1) is the most highly expressed peptide in endothelial cells and a potent vasoconstrictor, thus representing a potential therapeutic target. ET-1 plasma levels were measured in a cohort of 194 Covid-19 patients stratified according to the clinical severity of their illness. Hospitalised patients, including those who died and those developing acute myocardial or kidney injury, had significantly elevated ET-1 plasma levels during the acute phase of infection. The results support the hypothesis that endothelin receptor antagonists may provide clinical benefit for certain Covid-19 patients.

Ejemplares similares